CVRx, Inc. (NASDAQ:CVRX) Receives $11.40 Consensus Target Price from Brokerages

CVRx, Inc. (NASDAQ:CVRX) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $11.40.

Several brokerages have recently commented on CVRX. Canaccord Genuity Group raised their price target on CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of CVRx in a research report on Monday, December 29th. Finally, Cantor Fitzgerald boosted their price target on shares of CVRx from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, November 6th.

Institutional Trading of CVRx

A number of hedge funds have recently bought and sold shares of the stock. Mount Lucas Management LP purchased a new position in shares of CVRx in the 2nd quarter valued at $30,000. Larson Financial Group LLC boosted its position in CVRx by 155.6% during the fourth quarter. Larson Financial Group LLC now owns 5,426 shares of the company’s stock valued at $39,000 after purchasing an additional 3,303 shares in the last quarter. Intech Investment Management LLC bought a new stake in CVRx during the second quarter valued at about $59,000. R Squared Ltd purchased a new position in CVRx in the fourth quarter valued at about $74,000. Finally, AlphaQuest LLC raised its holdings in CVRx by 114.6% in the second quarter. AlphaQuest LLC now owns 13,106 shares of the company’s stock worth $77,000 after purchasing an additional 6,998 shares in the last quarter. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Stock Performance

Shares of NASDAQ:CVRX opened at $5.69 on Tuesday. The firm’s 50 day simple moving average is $7.24 and its 200-day simple moving average is $8.10. The company has a debt-to-equity ratio of 1.03, a quick ratio of 8.60 and a current ratio of 9.62. CVRx has a one year low of $4.30 and a one year high of $15.41. The firm has a market cap of $149.13 million, a PE ratio of -2.82 and a beta of 1.31.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). The firm had revenue of $16.02 million during the quarter, compared to analysts’ expectations of $15.75 million. CVRx had a negative net margin of 92.95% and a negative return on equity of 84.45%. As a group, equities analysts predict that CVRx will post -1.91 EPS for the current year.

Key Headlines Impacting CVRx

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: Revenue beat: CVRx reported Q4 revenue of $16.02M versus consensus ~$15.75M, a modest upside that shows continued top‑line demand for its implantable device business. CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
• Neutral Sentiment: Q1 revenue guidance provided: management set Q1 revenue guidance of $13.7M–$14.7M (consensus ≈ $14.3M). The range overlaps expectations but implies limited upside near the midpoint; EPS guidance in the released note appears omitted/unclear. Q4 press release / guidance
• Neutral Sentiment: Short‑interest reports in filings showed anomalous/zero values and NaN changes for February; the published data appears unreliable and shouldn’t be taken as confirmation of a new short squeeze or heavy shorting. (No clean supporting data available.)
• Negative Sentiment: EPS miss and weak profitability: CVRx reported a Q4 loss of $0.46/sh, missing the consensus loss of $0.42 and widening from last year. The company reported a negative net margin (~93%) and negative ROE (~84%), which highlights ongoing operating losses and cash‑burn concerns. CVRx earnings details and call
• Negative Sentiment: Investor lawsuits / regulatory risk: Two law firms (Pomerantz and Kirby McInerney) announced investigations into CVRx on behalf of shareholders, referencing prior weaker results and disclosure issues. Potential litigation increases legal risk, management distraction, and downside pressure on the stock while investigations proceed. Pomerantz investor alert

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.